JAK2 and acquired polycythemia vera: However, Sorensen et al. demonstrated that treatment with the JAK2 inhibitor ruxolitinib, alone or combined with interferon-alpha (IFNa), lowered the high expression levels of PD-1 and PD-L1 in samples from MF and PV patients compared with healthy donors [127].